id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-272015-1anph6qi	Dauby, Nicolas	The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment?	2020-10-17		.txt	text/plain	959	65	43	The observation by Lammers et al (Lammers et al.) that early HCQ treatment after admission at low dosage (2400 mg in total) is associated with lower risk of admission in intensive care unit coincides with large observational studies showing a lower mortality rate in patients exposed to HCQ therapy compared to no or other treatment. Another recent large cohort study of patients on low-dose HCQ for inflammatory disorders reported an association between chronic HCQ use and reduced mortality following SARS-CoV-2 infection (Gentry et al. The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study Longterm hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study	./cache/cord-272015-1anph6qi.txt	./txt/cord-272015-1anph6qi.txt